Severe infection risk in triple and quadruple therapy for anti-MDA5 antibody-positive dermatomyositis
Clinical Rheumatology · 2025
DOI: 10.1007/s10067-025-07445-5 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Rheumatology, 2025. Verfasst von Yoshitaka Ueda und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan. yuesan_kanagawa@yahoo.co.jp. Hauptthemen laut MEDLINE: Dermatomyositis, Interferon-Induced Helicase, IFIH1, Immunosuppressive Agents, Infections. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 17 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis (MDA5-DM) can be refractory to treatment, and a triple combination therapy (TCT) consisting of a glucocorticoid, cyclophosphamide, and a calcineurin inhibitor is widely used in induction therapy. For progressive or severe disease despite TCT, another immunosuppressive agent, such as a Janus kinase (JAK) inhibitor, may be added to the induction regimen. METHOD: A retrospective cohort study across two centers in Japan was undertaken between January 2016 and December 2024 evaluating patients with MDA5-DM receiving TCT or quadruple combination therapy (QCT) determining the presence of severe infection. The latter therapy consisted of the addition of a JAK inhibitor to the TCT. A severe infection was defined as Grade 3 or higher according to the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. RESULTS: There were 24 patients were included; TCT: n = 19 and QCT: n = 5. In the former, three (3/19, 16%), two (2/19, 11%), and three (3/19, 16%) patients had a severe bacterial infection, invasive fungal infection, and a CMV infection, respectively. In the QCT group, two (2/5, 40%), two (2/5, 40%), and four (4/5: 80%) patients had a severe bacterial infection, invasive fungal infection, and a CMV infection, respectively. CMV infections were significantly more frequent in the QCT group (p = 0.014). Both TCT and QCT groups had five patients each with a severe infection (5/19, 26% and 5/5, 100%, respectively) (p = 0.006). CONCLUSION: While both TCT and QCT have infection, the QCT group may be at a higher risk, hence highlighting the need for vigilance and adequate prophylaxis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan. yuesan_kanagawa@yahoo.co.jp.
- Department of Rheumatic Diseases, Tama-Nambu Chiiki Hospital, Tokyo, Japan.
- Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan.
Zitieren
APA
Ueda, Y., Chinen, N., Shimada, K., & Yokogawa, N. (2025). Severe infection risk in triple and quadruple therapy for anti-MDA5 antibody-positive dermatomyositis. Clinical Rheumatology. https://doi.org/10.1007/s10067-025-07445-5
Vancouver
Ueda Y, Chinen N, Shimada K, Yokogawa N. Severe infection risk in triple and quadruple therapy for anti-MDA5 antibody-positive dermatomyositis. Clinical Rheumatology. 2025. doi:10.1007/s10067-025-07445-5
BibTeX
@article{Ueda2025,
author = {Ueda, Yoshitaka and Chinen, Naofumi and Shimada, Kota and Yokogawa, Naoto},
title = {Severe infection risk in triple and quadruple therapy for anti-MDA5 antibody-positive dermatomyositis},
journal = {Clinical Rheumatology},
year = {2025},
doi = {10.1007/s10067-025-07445-5}
}
EUVIMED